series-a
Stage
1
Investors
About
Trestle develops implantable bioengineered kidney tissues to treat patients with end stage renal disease, aiming to reduce reliance on dialysis and address the shortage of donor kidneys.
Explore Trestle's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.